Drug Profile
Ecubectedin - PharmaMar
Alternative Names: PM-14Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator PharmaMar
- Class Acetates; Antineoplastics; Aza compounds; Heterocyclic compounds with 4 or more rings; Indoles; Small molecules; Spiro compounds
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Soft tissue sarcoma
- Phase I Prostate cancer
Most Recent Events
- 17 Aug 2023 Chemical structure information added
- 14 Jul 2023 Phase-I clinical trials in Prostate cancer (Monotherapy) (IV) (PharmaMar pipeline, July 2023)
- 14 Jul 2023 Phase-II clinical trials in Solid tumours (Monotherapy) (IV) (PharmaMar pipeline, July 2023)